Formulation: A crystalline solid
Formal Name: 7-(4-methyl-1-piperazinyl)-2(3H)-benzoxazolone, monohydrochloride
Purity: ≥98%
Formula Markup: C12H15N3O2 • HCl
Formula Weight: 269,7
Shelf life (days): 1460
CAS Number: 269718-83-4
Notes: Pardoprunox is a partial agonist of dopamine D2 and D3 receptors (EC50s = 10 and 0.63 nM, respectively) and a full agonist of the serotonin (5-HT) receptor subtype 5-HT1A (EC50 = 501 nM) in radioligand binding assays.{40413} It is selective for dopamine D2 and D3 and 5-HT1A receptors over a panel of neurotransmitter receptors (Kis = >1,000 nM). Pardoprunox reduces the accumulation of cAMP induced by forskolin (Item No. 11018) in a concentration-dependent manner and blocks quinpirole-induced inhibition of dopamine release (pA2 = 8.5) in rat striatal slices. Pardoprunox increases contralateral turning behavior in a 6-OHDA rat model of Parkinson’s disease (ED50 = 0.03 mg/kg).{40414} It also reduces hyperlocomotion induced by amphetamine (Item Nos. 14204 / 15650 / ISO60188) and induces 5-HT1A-mediated flat body posturing and lower lip retraction in rats. Pardoprunox (0.01-0.3 mg/kg) increases locomotor activity in a marmoset model of Parkinson’s disease induced by MPTP in a dose-dependent manner. Formulations containing pardoprunox are under clinical investigation for the treatment of Parkinson’s disease-associated motor fluctuations.{40415}
English
Deutsch
